Division of Surgical Oncology, Department of Surgery, Wake Forest University, Winston-Salem, North Carolina.
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia.
J Surg Oncol. 2019 Sep;120(3):340-347. doi: 10.1002/jso.25606. Epub 2019 Jun 27.
Resection of primary retroperitoneal sarcomas (RPS) has a high incidence of recurrence. This study aims to identify patterns of recurrence and its impact on overall survival.
Adult patients with primary retroperitoneal soft tissue sarcomas who underwent resection in 2000-2016 at eight institutions of the US Sarcoma Collaborative were evaluated.
Four hundred and ninety-eight patients were analyzed, with 56.2% (280 of 498) having recurrences. There were 433 recurrences (1-8) in 280 patients with 126 (25.3%) being locoregional, 82 (16.5%) distant, and 72 (14.5%) both locoregional and distant. Multivariate analyses revealed the following: Patient age P = .0002), tumor grade (P = .02), local recurrence (P = .0003) and distant recurrence (P < .0001) were predictors of disease-specific survival. The 1-, 3-, and 5-year survival rate for patients who recurred vs not was 89.6% (standard error [SE] 1.9) vs 93.5% (1.8), 66.0% (3.2) vs 88.4% (2.6), and 51.8% (3.6) vs 83.9% (3.3), respectively, P < .0001. Median survival was 5.3 years for the recurrence vs 11.3+ years for the no recurrence group (P < .0001). Median survival from the time of recurrence was 2.5 years.
Recurrence after resection of RPS occurs in more than half of patients independently of resection status or perioperative chemotherapy and is equally distributed between locoregional and distant sites. Recurrence is primarily related to tumor biology and is associated with a significant decrease in overall survival.
原发性腹膜后肉瘤(RPS)的切除术有很高的复发率。本研究旨在确定复发模式及其对总生存率的影响。
对 2000 年至 2016 年期间在美国肉瘤协作组的 8 个机构接受原发性腹膜后软组织肉瘤切除术的成年患者进行评估。
分析了 498 例患者,其中 56.2%(280/498)发生了复发。在 280 例有复发的患者中,有 433 例(1-8)复发,其中 126 例(25.3%)为局部复发,82 例(16.5%)为远处转移,72 例(14.5%)为局部和远处转移。多变量分析显示:患者年龄 P = .0002)、肿瘤分级(P = .02)、局部复发(P = .0003)和远处转移(P < .0001)是疾病特异性生存率的预测因素。与未复发患者相比,复发患者的 1 年、3 年和 5 年生存率分别为 89.6%(标准误差 [SE] 1.9)vs 93.5%(1.8)、66.0%(3.2)vs 88.4%(2.6)和 51.8%(3.6)vs 83.9%(3.3),P < .0001。复发组的中位生存期为 5.3 年,未复发组的中位生存期为 11.3+年(P < .0001)。从复发时起的中位生存时间为 2.5 年。
RPS 切除术后复发发生在超过一半的患者中,与切除状态或围手术期化疗无关,且在局部和远处部位分布均匀。复发主要与肿瘤生物学有关,并与总生存率显著下降相关。